{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&q=B-cell+ALL", "query": { "q": "B-cell ALL", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 10527, "total_pages": 1053, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=5&q=B-cell+ALL&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&q=B-cell+ALL&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T08:12:21.343Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00477191", "title": "Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psoriasis", "Metabolic Syndrome", "Hyperlipidemia", "Obesity", "Hypertension" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-05", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477191" }, { "nct_id": "NCT01705574", "title": "Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "ATV Placebo", "type": "DRUG" }, { "name": "RTV Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 583, "start_date": "2012-10-24", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 41, "location_summary": "Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705574" }, { "nct_id": "NCT00002750", "title": "Melphalan in Patients With Neoplastic Meningitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Extragonadal Germ Cell Tumor", "Leukemia", "Lymphoma", "Ovarian Cancer" ], "interventions": [ { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 6, "start_date": "1992-12", "completion_date": "2001-05", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002750" }, { "nct_id": "NCT00934518", "title": "Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Cancer of the Head and Neck" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-07", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00934518" }, { "nct_id": "NCT01149850", "title": "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "DNA methylation analysis", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "GENETIC" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 50, "start_date": "2010-04-28", "completion_date": "2023-12-08", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149850" }, { "nct_id": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Prolymphocytic Leukemia" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2014-12-22", "completion_date": "2025-10-22", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296918" }, { "nct_id": "NCT01639508", "title": "Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2012-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01639508" }, { "nct_id": "NCT00006708", "title": "S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2000-10", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 85, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006708" }, { "nct_id": "NCT00108108", "title": "Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "HCD122", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-04", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 5, "location_summary": "La Jolla, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Beech Grove", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108108" }, { "nct_id": "NCT05442515", "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-NHL", "B-Non Hodgkin Lymphoma", "Acute Lymphocytic Leukemia", "Acute Lymphoblastic Leukemia", "B-precursor ALL", "B-All", "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, B Cell", "B-Cell Lymphoma", "B-Cell Leukemia", "Acute Lymphoid Leukemia" ], "interventions": [ { "name": "CD19/CD22-CAR-transduced T cells", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 130, "start_date": "2022-12-28", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-07T08:12:21.343Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05442515" } ] }